Literature DB >> 19727148

Radiotherapy: encouraging early data for SBRT in prostate cancer.

May Abdel-Wahab, Alan Pollack.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19727148     DOI： 10.1038/nrurol.2009.166

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  8 in total

Review 1.  Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials?

Authors:  A Daşu
Journal:  Clin Oncol (R Coll Radiol)       Date:  2007-03-09       Impact factor: 4.126

Review 2.  High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results.

Authors:  D Jeffrey Demanes; Rodney R Rodriguez; Lionel Schour; David Brandt; Gillian Altieri
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-04-01       Impact factor: 7.038

3.  Fractionation and protraction for radiotherapy of prostate carcinoma.

Authors:  D J Brenner; E J Hall
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-03-15       Impact factor: 7.038

4.  Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial.

Authors:  Alan Pollack; Alexandra L Hanlon; Eric M Horwitz; Steven J Feigenberg; Andre A Konski; Benjamin Movsas; Richard E Greenberg; Robert G Uzzo; C-M Charlie Ma; Shawn W McNeeley; Mark K Buyyounouski; Robert A Price
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-19       Impact factor: 7.038

5.  Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results.

Authors:  Berit L Madsen; R Alex Hsi; Huong T Pham; Jack F Fowler; Laura Esagui; John Corman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-03-15       Impact factor: 7.038

6.  Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.

Authors:  Razvan M Galalae; Alvaro Martinez; Tim Mate; Christina Mitchell; Gregory Edmundson; Nils Nuernberg; Stephen Eulau; Gary Gustafson; Michael Gribble; Gyoergy Kovács
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-15       Impact factor: 7.038

7.  High-dose-rate brachytherapy as monotherapy for localized prostate cancer: a retrospective analysis with special focus on tolerance and chronic toxicity.

Authors:  Yasuo Yoshioka; Takayuki Nose; Ken Yoshida; Ryoong Jin Oh; Yuji Yamada; Eiichi Tanaka; Hideya Yamazaki; Takehiro Inoue; Toshihiko Inoue
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-05-01       Impact factor: 7.038

8.  Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.

Authors:  Christopher R King; James D Brooks; Harcharan Gill; Todd Pawlicki; Cristian Cotrutz; Joseph C Presti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-08-26       Impact factor: 7.038
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.